miércoles, 18 de febrero de 2009

Sensibilidad GLAXO...

Andrew Witty dictó una conferencia “Big Pharma as a Catalyst for Change” en Harvard Medical School el pasado 13 de febrero en la que siguió "desnudando sus intenciones".
En ella manifiestó una sensibilidad especial sobre problemas sanitarios de paises del tercer mundo.
Entre otras cosas dijo:

En cuanto a patentes:

First up is “a more flexible approach to IP in the least developed countries”. Stating that “IP’s primary objective is to incentivise and reward research”, he noted that “there are plenty of neglected tropical disease where there is a severe lack of research. We need to see if we can use IP to help address that gap”.

Specifically, GSK is proposing a “Least Developed Country Patent Pool” for medicines for neglected tropical diseases”. Mr Witty said that “we would put our relevant small molecule compounds or process patents” into the pool, allowing others access to develop and produce new products. “Any benefits from the pool must go in full and solely to LDCs”, he stressed.

En cuanto a precios:

he stated that GSK will reduce its prices for patented drugs in the LDCs so that they will be no higher than 25% of the developed world “assuming we can cover our cost of goods”. In middle income countries, “we will also be more flexible”, Mr Witty said, “so that prices reflect more closely a country’s ability to pay”.

En cuanto a investigación:

called for greater collaboration in fighting diseases of the developing world. He cited the example of GSK’s dedicated research centre into DDW in Tres Cantos, Spain which employs 100 scientists funded in part by partners such as Medicines for Malaria Venture and the Global Alliance for TB Drug Development. However, globally, research into DDW “is still too fragmented…we need to have much greater critical mass and partnership between the public and private sectors” he said.

En cuanto a colaboración:

“We need to stop saying ‘it’s not our fault there is no infrastructure to deliver healthcare’ and start saying ‘who can we work with to ensure that the infrastructure does exist’?” To do this, GSK will use 20% of the profit made in selling medicines in LDCs to reinvest in infrastructure projects in those countries. “We never want to be seen just as a ‘western’ company. We need to be a local company,” Mr Witty said.

Tomé "prestado" de PharmaGossip


No hay comentarios: